Johnson & Johnson (JNJ) : Sageworth Trust Co scooped up 268 additional shares in Johnson & Johnson during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 12, 2016. The investment management firm now holds a total of 6,524 shares of Johnson & Johnson which is valued at $718,814.Johnson & Johnson makes up approximately 0.17% of Sageworth Trust Co’s portfolio.
Johnson & Johnson opened for trading at $110.07 and hit $110.4 on the upside on Friday, eventually ending the session at $110.18, with a gain of 0.31% or 0.34 points. The heightened volatility saw the trading volume jump to 1,00,57,921 shares. Company has a market cap of $304,026 M.
Other Hedge Funds, Including , Gavekal Capital boosted its stake in JNJ in the latest quarter, The investment management firm added 35,664 additional shares and now holds a total of 103,675 shares of Johnson & Johnson which is valued at $11,422,912. Johnson & Johnson makes up approx 4.14% of Gavekal Capital’s portfolio.Dnb Asset Management As reduced its stake in JNJ by selling 54,074 shares or 5.67% in the most recent quarter. The Hedge Fund company now holds 898,825 shares of JNJ which is valued at $99,032,539. Johnson & Johnson makes up approx 2.04% of Dnb Asset Management As’s portfolio.Kessler Investment Group boosted its stake in JNJ in the latest quarter, The investment management firm added 892 additional shares and now holds a total of 18,835 shares of Johnson & Johnson which is valued at $2,052,450. Johnson & Johnson makes up approx 3.10% of Kessler Investment Group’s portfolio.Beacon Financial Group reduced its stake in JNJ by selling 2,985 shares or 3.0% in the most recent quarter. The Hedge Fund company now holds 96,648 shares of JNJ which is valued at $10,552,995. Johnson & Johnson makes up approx 2.28% of Beacon Financial Group’s portfolio.
On the company’s financial health, Johnson & Johnson reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jan 26, 2016. Analyst had a consensus of $1.42. The company had revenue of $17811.00 million for the quarter, compared to analysts expectations of $17856.07 million. The company’s revenue was down -2.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.27 EPS.
Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by RBC Capital Mkts on Apr 15, 2016 to “Outperform”, Firm has raised the Price Target to $ 122 from a previous price target of $114 .Johnson & Johnson was Upgraded by Goldman to ” Neutral” on Mar 14, 2016.
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.